PATIENTS & CARE PARTNERS Putting patients and their families first

We are rethinking care and how it is delivered to help patients and families impacted by brain health disorders.

See our resources for patients
Asian woman on a solid blue background wearing a gray t-shirt and a ponytail looking off into the distance

News The latest from Sage

press releases & statements

Read the latest news on Sage and our work.

Investor Events & Presentations

See upcoming events and access prior Sage presentations.

Sage Medical Hub

Search our library of medical resources, contact a Medical Science Liaison, submit a medical inquiry, and more. For US Healthcare Professionals.

sage medical hub
See All News

Product and Clinical Stage Pipeline

Sage Pipeline

*Under a collaboration agreement between Sage and Shionogi & Co., Ltd., Shionogi has the right to develop and commercialize zuranolone in Japan, Taiwan, and South Korea.
**Biogen terminated its rights as to the SAGE-324 program in September 2024; the termination will be effective on February 17, 2025.

Please refer to the U.S. Prescribing Information for ZURZUVAE
Safety and efficacy for investigational uses or compounds have not been established. There is no guarantee that the outcome of these studies will be positive or result in approval by a health authority.

LEARN MORE ABOUT OUR PROGRAMS AND RESEARCH